Vistagen Therapeutics (VTGN) News Today

Vistagen Therapeutics logo
$2.97 +0.12 (+4.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.86 -0.11 (-3.54%)
As of 04:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (NASDAQ:VTGN) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS
Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.48) by $0.02. Vistagen Therapeutics had a negative return on equity of 36.35% and a negative net margin of 4,521.71%.
Q3 2025 Vistagen Therapeutics Inc Earnings Call Transcript
Vistagen reports Q3 EPS (46c) vs (22c) last year
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50-Day Moving Average - Here's Why
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average - What's Next?
Vistagen granted USPTO patent for AV-101 to treat neuropathic pain
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (VTGN) to Release Quarterly Earnings on Tuesday
Vistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports.
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Sees Large Increase in Short Interest
Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 658,100 shares, a growth of 46.2% from the December 31st total of 450,000 shares. Approximately 2.6% of the shares of the company are short sold. Based on an average trading volume of 276,000 shares, the short-interest ratio is currently 2.4 days.
Vistagen announces results from PH284 study in cancer cachexia
Vistagen enrolls first patient in repeat dose study of fasedienol
Vistagen Therapeutics, Inc. stock logo
Great Point Partners LLC Sells 855,263 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Great Point Partners LLC decreased its stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 55.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 674,075 shares of the company's stock afte
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Short Interest Update
Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report) was the recipient of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 528,200 shares, a decrease of 18.1% from the October 15th total of 644,700 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.1% of the shares of the company are sold short.
Vistagen Therapeutics, Inc. stock logo
Research Analysts Set Expectations for VTGN Q1 Earnings
Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share estimates for Vistagen Therapeutics in a report released on Thursday, November 7th. William Blair analyst M. Minter expects that the company will post earn
Vistagen Therapeutics Reports Increased R&D Expenses
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (VTGN) Scheduled to Post Earnings on Thursday
Vistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.
Vistagen Therapeutics, Inc. stock logo
Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN)
Great Point Partners LLC lowered its holdings in shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) by 17.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 1,529,338 shares of the company's stock after selling 329,397 shares during the per
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50 Day Moving Average of $3.52
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above Fifty Day Moving Average of $3.49
Vistagen Therapeutics, Inc. stock logo
Q2 2025 EPS Estimates for Vistagen Therapeutics, Inc. Lifted by Analyst (NASDAQ:VTGN)
Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Stock analysts at William Blair increased their Q2 2025 earnings per share estimates for Vistagen Therapeutics in a research report issued to clients and investors on Wednesday, August 14th. William Blair analyst T. Lugo now expects that t
Here's what to expect from VistaGen Therapeutics's earnings
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (VTGN) Scheduled to Post Quarterly Earnings on Tuesday
Vistagen Therapeutics (NASDAQ:VTGN) will be releasing earnings after the market closes on Tuesday, August 13, Zacks reports.
Vistagen Therapeutics, Inc. stock logo
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below 50-Day Moving Average of $3.60
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Below 50-Day Moving Average of $3.60
3 Stocks Under $15 That Could Make You a Millionaire
Vistagen Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for Vistagen Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:VTGN)
Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Free Report) - Equities research analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for shares of Vistagen Therapeutics in a research note issued to investors on Wednesday, June 12th. William Blair analyst T. Lugo now anti
Get Vistagen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.

VTGN Media Mentions By Week

VTGN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VTGN
News Sentiment

0.21

0.39

Average
Medical
News Sentiment

VTGN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VTGN Articles
This Week

10

1

VTGN Articles
Average Week

Get Vistagen Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:VTGN) was last updated on 2/14/2025 by MarketBeat.com Staff
From Our Partners